DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations
Annals of Hematology · 27.03.2026 · 105 (4)
DOI: 10.1007/s00277-026-06934-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 27.03.2026. Verfasst von Aya Mohamed Adel Arafat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. aya.arafat@kasralainy.edu.eg. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Aspartyl-tRNA synthetase (DARS) is implicated in several cancers, but its role in BCR::ABL-negative JAK2V617F-positive myeloproliferative neoplasms (MPNs) is unclear. This study evaluated DARS expression in MPN subtypes and its associations with clinical parameters and survival. Diagnostic bone marrow biopsies from 121 JAK2V617F-positive MPN patients (PV, n = 34; ET, n = 25; PMF, n = 54; MPN-U, n = 8) were stained on a Ventana BenchMark XT immunostainer using anti-DARS antibody (ABclonal A6574). DARS immunoreactive score (IRS) was determined by multiplying intensity (0–3) and percentage of positive cells (0–4). Inter-observer agreement was excellent (κ = 0.89, 95% CI: 0.83–0.95). Patients were stratified using the cohort’s median cutoff (IRS = 9) for survival analysis. Statistical tests included Kruskal-Wallis with effect sizes and multivariate Cox regression. DARS IRS differed across subtypes (H = 14.19, p = 0.003, η²=0.10): PV median 9 with IQR (9–12), ET 9 (8–12), PMF 8 (6–9), and MPN-U 10.5 (6–12). PV vs. PMF differences: intensity p = 0.001 (r = 0.35), IRS p < 0.001 (r = 0.38). DARS IRS correlated inversely with spleen size (ρ=–0.266, p = 0.003, 95% CI: − 0.43 to − 0.09), LDH (ρ=–0.194, p = 0.033), and fibrosis grade (ρ=–0.280, p = 0.002), and positively with hemoglobin (ρ = 0.308, p = 0.001, 95% CI: 0.13–0.47). High DARS expression independently predicted improved leukemia-free survival (LFS) (HR = 0.42, p = 0.007, 95% CI: 0.22–0.80) after adjusting for age, subtype, and fibrosis. DARS is differentially expressed in MPN subtypes. Its association with enhanced LFS identifies DARS as a potential prognostic biomarker warranting validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt. aya.arafat@kasralainy.edu.eg.
- Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
- Department of Pathology, Faculty of Medicine, Alasmarya Islamic University, Zliten, Libya.
- Department of Internal Medicine, Clinical Hematology Unit, Kasr Al Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Förderung
- Cairo University
Zitieren
APA
Arafat, A. M. A., Ghaffar, H. A. A., Khallaf, A. M., Younes, S. A. M., Morad, M. A., & Mahgoub, S. M. A. (2026). DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06934-0
Vancouver
Arafat AMA, Ghaffar HAA, Khallaf AM, Younes SAM, Morad MA, Mahgoub SMA. DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06934-0
BibTeX
@article{Arafat2026,
author = {Arafat, Aya Mohamed Adel and Ghaffar, Heba Adel AbdEl and Khallaf, Ahmed M and Younes, Sufyan Ahmed Mokhtar and Morad, Mohamed Abdelkader and Mahgoub, Shirihan Mahmoud Anwar},
title = {DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {4},
doi = {10.1007/s00277-026-06934-0}
}
EUVIMED